Global Human Chorionic Gonadotropin

Human Chorionic Gonadotropin Comprehensive Study by Technology (Natural Source Extraction, Recombinant Technology), End User (Fertility Clinics, Research Institutions, Others), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, Others) Players and Region - Global Market Outlook to 2026

Human Chorionic Gonadotropin Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Human Chorionic Gonadotropin Market?

The human chorionic gonadotropin hormone plays a different role in both male & female sexual development. In females, the human chorionic gonadotropin mostly used to identify defects and confirm pregnancy and it is made from the placenta during pregnancy which nourishes the egg after it has been fertilized. In males, especially young boys it used to increase sperm count. Human chorionic gonadotropin is administrated in the body through the injection under the skin into the muscle. Growing phenomenal pace since the past few years due to rise in infertility in women and changing lifestyles and poor dietary habits among the men and women are expected to make significant growth of the global human chorionic gonadotropin market.

The market study is being classified and major geographies with country level break-up.

Bristol Myers Squibb (United States), Merck & Co., Inc. (United States), Cigna (United States), Lee BioSolutions Inc. (United States), Scripps Laboratories (United States), Ferring Pharmaceuticals Inc. (United States), Fresenius Kabi AG (Germany), MyBioSource (United States), Kamiya Biomedical Company (United States), Sun Pharmaceutical Industries Ltd. (India), Cipla Limited (India), Sanzyme (India) and LUPIN (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Intas Pharmaceuticals (India), Prospec-Tany Technogene Ltd (Israel), Biocare Medical, LLC (United States), Zydus Cadila (India) and Life Medicare & Biotech Pvt. Ltd. (India).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Human Chorionic Gonadotropin market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Human Chorionic Gonadotropin market by Type, Application and Region.

On the basis of geography, the market of Human Chorionic Gonadotropin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Incidence of Male Hypogonadism among the Geriatric Population
  • Growing in Traction Gained by Human Chorionic Gonadotropin among Healthcare Professionals and Patients

Market Trend
  • Rise in Availability of Treatment and Services Regarding Infertility

Restraints
  • Various Side-Effects Associated with Using Human Chorionic Gonadotropin as a Treatment

Opportunities
  • Increase in Awareness about Therapeutics for Infertility Issues are Boosting the Demand for Human Chorionic Gonadotropin Hormone in Developing Countries

Challenges
  • Strict Norms and Regulation Regarding the Human Chorionic Gonadotropin


On 22nd January 2020, Merck has announced that the European Commission (EC) has granted Marketing Authorization (MA) for its new GONAL-f (follitropin alfa) 150 IU pen. This means Merck now offers an even more comprehensive range of best-in-class pens, supporting patients from the beginning to the end of their fertility stimulation cycle, and when lower doses are required.


Key Target Audience
Human Chorionic Gonadotropin Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Report Objectives / Segmentation Covered

By Technology
  • Natural Source Extraction
  • Recombinant Technology

By End User
  • Fertility Clinics
  • Research Institutions
  • Others

By Therapeutic Area
  • Female Infertility Treatment
  • Male Hypogonadism
  • Oligospermic Treatment
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence of Male Hypogonadism among the Geriatric Population
      • 3.2.2. Growing in Traction Gained by Human Chorionic Gonadotropin among Healthcare Professionals and Patients
    • 3.3. Market Challenges
      • 3.3.1. Strict Norms and Regulation Regarding the Human Chorionic Gonadotropin
    • 3.4. Market Trends
      • 3.4.1. Rise in Availability of Treatment and Services Regarding Infertility
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Chorionic Gonadotropin, by Technology, End User, Therapeutic Area and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Human Chorionic Gonadotropin (Value)
      • 5.2.1. Global Human Chorionic Gonadotropin by: Technology (Value)
        • 5.2.1.1. Natural Source Extraction
        • 5.2.1.2. Recombinant Technology
      • 5.2.2. Global Human Chorionic Gonadotropin by: End User (Value)
        • 5.2.2.1. Fertility Clinics
        • 5.2.2.2. Research Institutions
        • 5.2.2.3. Others
      • 5.2.3. Global Human Chorionic Gonadotropin by: Therapeutic Area (Value)
        • 5.2.3.1. Female Infertility Treatment
        • 5.2.3.2. Male Hypogonadism
        • 5.2.3.3. Oligospermic Treatment
        • 5.2.3.4. Others
      • 5.2.4. Global Human Chorionic Gonadotropin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Human Chorionic Gonadotropin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol Myers Squibb (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co., Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cigna (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lee BioSolutions Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Scripps Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ferring Pharmaceuticals Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fresenius Kabi AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MyBioSource (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Kamiya Biomedical Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Cipla Limited (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sanzyme (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. LUPIN (India)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Human Chorionic Gonadotropin Sale, by Technology, End User, Therapeutic Area and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Human Chorionic Gonadotropin (Value)
      • 7.2.1. Global Human Chorionic Gonadotropin by: Technology (Value)
        • 7.2.1.1. Natural Source Extraction
        • 7.2.1.2. Recombinant Technology
      • 7.2.2. Global Human Chorionic Gonadotropin by: End User (Value)
        • 7.2.2.1. Fertility Clinics
        • 7.2.2.2. Research Institutions
        • 7.2.2.3. Others
      • 7.2.3. Global Human Chorionic Gonadotropin by: Therapeutic Area (Value)
        • 7.2.3.1. Female Infertility Treatment
        • 7.2.3.2. Male Hypogonadism
        • 7.2.3.3. Oligospermic Treatment
        • 7.2.3.4. Others
      • 7.2.4. Global Human Chorionic Gonadotropin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Chorionic Gonadotropin: by Technology(USD Million)
  • Table 2. Human Chorionic Gonadotropin Natural Source Extraction , by Region USD Million (2015-2020)
  • Table 3. Human Chorionic Gonadotropin Recombinant Technology , by Region USD Million (2015-2020)
  • Table 4. Human Chorionic Gonadotropin: by End User(USD Million)
  • Table 5. Human Chorionic Gonadotropin Fertility Clinics , by Region USD Million (2015-2020)
  • Table 6. Human Chorionic Gonadotropin Research Institutions , by Region USD Million (2015-2020)
  • Table 7. Human Chorionic Gonadotropin Others , by Region USD Million (2015-2020)
  • Table 8. Human Chorionic Gonadotropin: by Therapeutic Area(USD Million)
  • Table 9. Human Chorionic Gonadotropin Female Infertility Treatment , by Region USD Million (2015-2020)
  • Table 10. Human Chorionic Gonadotropin Male Hypogonadism , by Region USD Million (2015-2020)
  • Table 11. Human Chorionic Gonadotropin Oligospermic Treatment , by Region USD Million (2015-2020)
  • Table 12. Human Chorionic Gonadotropin Others , by Region USD Million (2015-2020)
  • Table 13. South America Human Chorionic Gonadotropin, by Country USD Million (2015-2020)
  • Table 14. South America Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 15. South America Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 16. South America Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 17. Brazil Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 18. Brazil Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 19. Brazil Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 20. Argentina Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 21. Argentina Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 22. Argentina Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 23. Rest of South America Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 24. Rest of South America Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 25. Rest of South America Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 26. Asia Pacific Human Chorionic Gonadotropin, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 28. Asia Pacific Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 29. Asia Pacific Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 30. China Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 31. China Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 32. China Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 33. Japan Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 34. Japan Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 35. Japan Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 36. India Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 37. India Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 38. India Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 39. South Korea Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 40. South Korea Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 41. South Korea Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 42. Taiwan Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 43. Taiwan Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 44. Taiwan Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 45. Australia Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 46. Australia Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 47. Australia Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 51. Europe Human Chorionic Gonadotropin, by Country USD Million (2015-2020)
  • Table 52. Europe Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 53. Europe Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 54. Europe Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 55. Germany Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 56. Germany Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 57. Germany Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 58. France Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 59. France Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 60. France Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 61. Italy Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 62. Italy Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 63. Italy Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 64. United Kingdom Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 65. United Kingdom Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 66. United Kingdom Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 67. Netherlands Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 68. Netherlands Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 69. Netherlands Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 70. Rest of Europe Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 71. Rest of Europe Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 72. Rest of Europe Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 73. MEA Human Chorionic Gonadotropin, by Country USD Million (2015-2020)
  • Table 74. MEA Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 75. MEA Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 76. MEA Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 77. Middle East Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 78. Middle East Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 79. Middle East Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 80. Africa Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 81. Africa Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 82. Africa Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 83. North America Human Chorionic Gonadotropin, by Country USD Million (2015-2020)
  • Table 84. North America Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 85. North America Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 86. North America Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 87. United States Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 88. United States Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 89. United States Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 90. Canada Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 91. Canada Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 92. Canada Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 93. Mexico Human Chorionic Gonadotropin, by Technology USD Million (2015-2020)
  • Table 94. Mexico Human Chorionic Gonadotropin, by End User USD Million (2015-2020)
  • Table 95. Mexico Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2015-2020)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Human Chorionic Gonadotropin: by Technology(USD Million)
  • Table 110. Human Chorionic Gonadotropin Natural Source Extraction , by Region USD Million (2021-2026)
  • Table 111. Human Chorionic Gonadotropin Recombinant Technology , by Region USD Million (2021-2026)
  • Table 112. Human Chorionic Gonadotropin: by End User(USD Million)
  • Table 113. Human Chorionic Gonadotropin Fertility Clinics , by Region USD Million (2021-2026)
  • Table 114. Human Chorionic Gonadotropin Research Institutions , by Region USD Million (2021-2026)
  • Table 115. Human Chorionic Gonadotropin Others , by Region USD Million (2021-2026)
  • Table 116. Human Chorionic Gonadotropin: by Therapeutic Area(USD Million)
  • Table 117. Human Chorionic Gonadotropin Female Infertility Treatment , by Region USD Million (2021-2026)
  • Table 118. Human Chorionic Gonadotropin Male Hypogonadism , by Region USD Million (2021-2026)
  • Table 119. Human Chorionic Gonadotropin Oligospermic Treatment , by Region USD Million (2021-2026)
  • Table 120. Human Chorionic Gonadotropin Others , by Region USD Million (2021-2026)
  • Table 121. South America Human Chorionic Gonadotropin, by Country USD Million (2021-2026)
  • Table 122. South America Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 123. South America Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 124. South America Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 125. Brazil Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 126. Brazil Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 127. Brazil Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 128. Argentina Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 129. Argentina Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 130. Argentina Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 131. Rest of South America Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 132. Rest of South America Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 133. Rest of South America Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 134. Asia Pacific Human Chorionic Gonadotropin, by Country USD Million (2021-2026)
  • Table 135. Asia Pacific Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 136. Asia Pacific Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 137. Asia Pacific Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 138. China Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 139. China Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 140. China Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 141. Japan Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 142. Japan Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 143. Japan Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 144. India Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 145. India Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 146. India Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 147. South Korea Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 148. South Korea Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 149. South Korea Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 150. Taiwan Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 151. Taiwan Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 152. Taiwan Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 153. Australia Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 154. Australia Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 155. Australia Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 159. Europe Human Chorionic Gonadotropin, by Country USD Million (2021-2026)
  • Table 160. Europe Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 161. Europe Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 162. Europe Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 163. Germany Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 164. Germany Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 165. Germany Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 166. France Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 167. France Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 168. France Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 169. Italy Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 170. Italy Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 171. Italy Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 172. United Kingdom Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 173. United Kingdom Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 174. United Kingdom Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 175. Netherlands Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 176. Netherlands Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 177. Netherlands Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 178. Rest of Europe Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 179. Rest of Europe Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 180. Rest of Europe Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 181. MEA Human Chorionic Gonadotropin, by Country USD Million (2021-2026)
  • Table 182. MEA Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 183. MEA Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 184. MEA Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 185. Middle East Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 186. Middle East Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 187. Middle East Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 188. Africa Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 189. Africa Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 190. Africa Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 191. North America Human Chorionic Gonadotropin, by Country USD Million (2021-2026)
  • Table 192. North America Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 193. North America Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 194. North America Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 195. United States Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 196. United States Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 197. United States Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 198. Canada Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 199. Canada Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 200. Canada Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 201. Mexico Human Chorionic Gonadotropin, by Technology USD Million (2021-2026)
  • Table 202. Mexico Human Chorionic Gonadotropin, by End User USD Million (2021-2026)
  • Table 203. Mexico Human Chorionic Gonadotropin, by Therapeutic Area USD Million (2021-2026)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Chorionic Gonadotropin: by Technology USD Million (2015-2020)
  • Figure 5. Global Human Chorionic Gonadotropin: by End User USD Million (2015-2020)
  • Figure 6. Global Human Chorionic Gonadotropin: by Therapeutic Area USD Million (2015-2020)
  • Figure 7. South America Human Chorionic Gonadotropin Share (%), by Country
  • Figure 8. Asia Pacific Human Chorionic Gonadotropin Share (%), by Country
  • Figure 9. Europe Human Chorionic Gonadotropin Share (%), by Country
  • Figure 10. MEA Human Chorionic Gonadotropin Share (%), by Country
  • Figure 11. North America Human Chorionic Gonadotropin Share (%), by Country
  • Figure 12. Global Human Chorionic Gonadotropin share by Players 2020 (%)
  • Figure 13. Global Human Chorionic Gonadotropin share by Players (Top 3) 2020(%)
  • Figure 14. Global Human Chorionic Gonadotropin share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 17. Bristol Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 18. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Cigna (United States) Revenue, Net Income and Gross profit
  • Figure 21. Cigna (United States) Revenue: by Geography 2020
  • Figure 22. Lee BioSolutions Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Lee BioSolutions Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Scripps Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 25. Scripps Laboratories (United States) Revenue: by Geography 2020
  • Figure 26. Ferring Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Ferring Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Fresenius Kabi AG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Fresenius Kabi AG (Germany) Revenue: by Geography 2020
  • Figure 30. MyBioSource (United States) Revenue, Net Income and Gross profit
  • Figure 31. MyBioSource (United States) Revenue: by Geography 2020
  • Figure 32. Kamiya Biomedical Company (United States) Revenue, Net Income and Gross profit
  • Figure 33. Kamiya Biomedical Company (United States) Revenue: by Geography 2020
  • Figure 34. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 35. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2020
  • Figure 36. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 37. Cipla Limited (India) Revenue: by Geography 2020
  • Figure 38. Sanzyme (India) Revenue, Net Income and Gross profit
  • Figure 39. Sanzyme (India) Revenue: by Geography 2020
  • Figure 40. LUPIN (India) Revenue, Net Income and Gross profit
  • Figure 41. LUPIN (India) Revenue: by Geography 2020
  • Figure 42. Global Human Chorionic Gonadotropin: by Technology USD Million (2021-2026)
  • Figure 43. Global Human Chorionic Gonadotropin: by End User USD Million (2021-2026)
  • Figure 44. Global Human Chorionic Gonadotropin: by Therapeutic Area USD Million (2021-2026)
  • Figure 45. South America Human Chorionic Gonadotropin Share (%), by Country
  • Figure 46. Asia Pacific Human Chorionic Gonadotropin Share (%), by Country
  • Figure 47. Europe Human Chorionic Gonadotropin Share (%), by Country
  • Figure 48. MEA Human Chorionic Gonadotropin Share (%), by Country
  • Figure 49. North America Human Chorionic Gonadotropin Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol Myers Squibb (United States)
  • Merck & Co., Inc. (United States)
  • Cigna (United States)
  • Lee BioSolutions Inc. (United States)
  • Scripps Laboratories (United States)
  • Ferring Pharmaceuticals Inc. (United States)
  • Fresenius Kabi AG (Germany)
  • MyBioSource (United States)
  • Kamiya Biomedical Company (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Cipla Limited (India)
  • Sanzyme (India)
  • LUPIN (India)
Additional players considered in the study are as follows:
Intas Pharmaceuticals (India) , Prospec-Tany Technogene Ltd (Israel) , Biocare Medical, LLC (United States) , Zydus Cadila (India) , Life Medicare & Biotech Pvt. Ltd. (India)
Select User Access Type

Key Highlights of Report


Jan 2021 218 Pages 87 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Chorionic Gonadotropin Quantitative research analysis
Global Human Chorionic Gonadotropin Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rising Incidence of Male Hypogonadism among the Geriatric Population " is seen as one of major growth factors of Human Chorionic Gonadotropin Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Human Chorionic Gonadotropin Report?

Have a Query? Click Here

Other Related Reports

Hib Vaccine Comprehensive Study by Type (Type 1-HIB Vaccine, Type 2- DTaP-IPV), Form (Liquid Monovalent HIB, Liquid Combination HIB, Lyophilized Monovalent HIB, Lyophilized Combination HIB), Age Grou...
$ 3750
Breast Cancer Predictive Genetic Testing Comprehensive Study by Type (High Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes), Application (Hospitals, Clinic Center, Pharmaceuticals,...
$ 3500
Adenovirus Vaccine Comprehensive Study by Type (Type 4 Vaccine, Type 7 Vaccine), Application (Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others) Players and Region - ...
$ 3500
Allergic Rhinitis Drugs Comprehensive Study by Type (Corticosteroids, Antihistamines, Vasoconstrictors, Pratropium Bromide, Others (Leukotrienes, Cromoglycate)), Application (Non-Allergic Rhinitis, M...
$ 3650
Dental Drugs Comprehensive Study by Type (Analgesic, Anesthetics, Antibiotics, Antifungals, Antiseptics, Fluorides, Benzodiazepines, Saliva Substitutes), Mode of Administration (Injectable, Oral, Spr...
$ 3450
Clarityne Comprehensive Study by Type (Loratadine Tablet, Loratadine Capsule, Loratadine Syrup), Application (Adult Drug, Pediatric Drug), Sales Channel (Hospitals, Drug Store, Specialty Pharmacy, E-...
$ 3500